Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00870324 · ClinicalTrials.gov registry record
OptiSense™ Performance in Detecting Atrial Episodes
A clinical trial of Atrial Fibrillation and Tachyarrhythmias, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 50
- Enrollment target
- 2
- Study locations
NCT00870324: Completed study of Atrial Fibrillation and Tachyarrhythmias, sponsored by Abbott Medical Devices.
NCT00870324 is a study of Atrial Fibrillation and Tachyarrhythmias that has completed, run by Abbott Medical Devices. The registered enrollment target is 50 participants, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00870324, a study of Atrial Fibrillation and Tachyarrhythmias, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The SENSE-AF study aims to determine the performance of the OptiSense lead in sensing fine episodes of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) and rejecting Far-Field R Wave (FFRW). The performance of the lead will be measured as a difference in device-determined time in AT/AF and surface-ECG determined time in AT/AF. This measurement will be compared to the control group which will be randomized to receive SJM's Tendril™ RA leads.
Conditions Studied
Interventions
- DEVICE OptiSense Lead
- DEVICE Tendril Lead
Study Locations (2)
Ohio
- Northeast Ohio Cardiovascular Specialists - Akron
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-09 |
What the finished NCT00870324 record still lists
NCT00870324 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which OptiSense Lead is the first listed.
NCT00870324 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00870324 about?
NCT00870324 is a clinical study titled "OptiSense™ Performance in Detecting Atrial Episodes". The SENSE-AF study aims to determine the performance of the OptiSense lead in sensing fine episodes of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) and rejecting Far-Field R Wave (FFRW). The performance of the lead will be measured as a difference in device-determined time in AT/AF and surface...
What is the current status of trial NCT00870324?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2009-03. Estimated completion is 2010-09.
What conditions does trial NCT00870324 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Tachyarrhythmias.
What interventions are being tested in trial NCT00870324?
The interventions under investigation include: OptiSense Lead (DEVICE), Tendril Lead (DEVICE).
Who is sponsoring clinical trial NCT00870324?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00870324 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00870324's enrollment target sits among peer trials
50 174th of 202 higher than 25 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia